Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high‐risk relapsed/refractory Hodgkin lymphoma is a research paper published in HemaSphere (2025). On theSindex it has a DataRank of 0. It has been cited 8 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: P50 CA107399‐11A1
NCI NIH HHS
Grant: P50 CA107399
National Institutes of Health
Grant: 5P50CA107399-05
Career Development Program
Bristol-Myers Squibb
FWCI
6.37
Citation Percentile
1.0%
Citation Trend
Fields of Study
Keywords